| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ADDR.2008.11.003 |
| P8608 | Fatcat ID | release_q2oa3gf6hvamhp7ljfumc2454u |
| P932 | PMC publication ID | 3105088 |
| P698 | PubMed publication ID | 19135109 |
| P5875 | ResearchGate publication ID | 23769394 |
| P50 | author | Kenneth Kin Wah To | Q55458847 |
| Rob Robey | Q58798575 | ||
| Susan E Bates | Q88874526 | ||
| Michael Dean | Q37841464 | ||
| P2093 | author name string | Patricia Fetsch | |
| Orsolya Polgar | |||
| Marius Dohse | |||
| P2860 | cites work | A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance | Q22008526 |
| Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line | Q24338329 | ||
| Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface | Q24553151 | ||
| ABC Transporters: From Microorganisms to Man | Q28181688 | ||
| The human ATP-binding cassette (ABC) transporter superfamily | Q28204495 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors | Q28214940 | ||
| Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line | Q28567948 | ||
| Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s) | Q28569107 | ||
| Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat | Q28572818 | ||
| The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype | Q29615563 | ||
| Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo | Q29619355 | ||
| Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene | Q30724183 | ||
| The GxxxG motif: a framework for transmembrane helix-helix association | Q30839523 | ||
| The expression and functional characterization of ABCG2 in brain endothelial cells and vessels | Q30980421 | ||
| Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes | Q31932176 | ||
| An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain | Q31936637 | ||
| Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells | Q42053730 | ||
| The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. | Q42466925 | ||
| N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane | Q42476415 | ||
| The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding | Q42497704 | ||
| Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect | Q42503887 | ||
| Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression | Q42814970 | ||
| The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme | Q42830333 | ||
| Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. | Q43579744 | ||
| Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. | Q43739398 | ||
| Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. | Q44245530 | ||
| C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. | Q44246870 | ||
| Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer | Q44396425 | ||
| Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier | Q44410490 | ||
| Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells | Q44490307 | ||
| Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro | Q44525894 | ||
| Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. | Q44747134 | ||
| Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Q44769964 | ||
| Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene | Q44769966 | ||
| Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. | Q44826211 | ||
| Isolation and genetic characterization of human KB cell lines resistant to multiple drugs | Q44844584 | ||
| Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. | Q44883138 | ||
| Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium | Q44898058 | ||
| Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | Q44960521 | ||
| Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies | Q44991784 | ||
| Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice | Q45023481 | ||
| Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias | Q45178457 | ||
| The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. | Q45246954 | ||
| Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. | Q45305094 | ||
| Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice | Q46413821 | ||
| Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells | Q46448053 | ||
| Effect of ABCG2 genotype on the oral bioavailability of topotecan | Q46503033 | ||
| The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta | Q46536640 | ||
| Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract | Q46584750 | ||
| Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk | Q46586540 | ||
| The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib | Q46617229 | ||
| Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. | Q46656254 | ||
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity | Q46726161 | ||
| P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan | Q46920680 | ||
| Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta | Q46960810 | ||
| Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes | Q46967012 | ||
| Evolution of the vertebrate ABC gene family: analysis of gene birth and death | Q48090918 | ||
| Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar | Q48230991 | ||
| Isolation and characterization of an anthracycline-resistant human leukemic cell line. | Q48543772 | ||
| Short communication: a polymorphism in ABCG2 in Bos indicus and Bos taurus cattle breeds. | Q50474210 | ||
| Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. | Q52171281 | ||
| Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. | Q53408008 | ||
| Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier | Q57374265 | ||
| Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep | Q61736943 | ||
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. | Q64911638 | ||
| Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines | Q72561176 | ||
| Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan | Q73088375 | ||
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib | Q79407999 | ||
| Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia | Q79455910 | ||
| Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors | Q79608737 | ||
| The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice | Q80229300 | ||
| Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2 | Q80777899 | ||
| ABCG2: structure, function and role in drug response | Q80968077 | ||
| Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse | Q81038641 | ||
| MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer | Q81240787 | ||
| The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib | Q81604961 | ||
| Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2 | Q95800148 | ||
| Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. | Q36846027 | ||
| Part II: management of resistance to imatinib in chronic myeloid leukaemia | Q37022464 | ||
| Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens | Q38299812 | ||
| Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. | Q38442081 | ||
| Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines | Q38498733 | ||
| ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. | Q39953815 | ||
| Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds | Q40005555 | ||
| ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition | Q40017306 | ||
| In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs | Q40030959 | ||
| The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study | Q40035590 | ||
| Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells | Q40043860 | ||
| Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5 | Q40097205 | ||
| Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. | Q40105359 | ||
| Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity | Q40136502 | ||
| The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. | Q40145054 | ||
| Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor | Q40220295 | ||
| Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo | Q40254328 | ||
| Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage | Q40278791 | ||
| Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse | Q40281717 | ||
| Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate | Q40289723 | ||
| Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. | Q40293727 | ||
| Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences | Q40324109 | ||
| Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion | Q40325508 | ||
| Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells | Q40340314 | ||
| Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. | Q40402929 | ||
| Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin | Q40409926 | ||
| Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists | Q40417118 | ||
| Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). | Q40431648 | ||
| Cyclosporin A is a broad-spectrum multidrug resistance modulator | Q40443016 | ||
| Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. | Q40446340 | ||
| The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. | Q40458879 | ||
| Mutational analysis of ABCG2: role of the GXXXG motif | Q40534113 | ||
| High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter | Q40553425 | ||
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro | Q40571040 | ||
| Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. | Q40624976 | ||
| The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. | Q40626046 | ||
| Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material | Q40633176 | ||
| MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models | Q40667580 | ||
| Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization | Q40755310 | ||
| Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. | Q40904151 | ||
| Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. | Q40985808 | ||
| Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations | Q41295118 | ||
| Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells | Q41594260 | ||
| Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. | Q41721659 | ||
| Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein | Q41730997 | ||
| Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. | Q41792411 | ||
| Akt signaling regulates side population cell phenotype via Bcrp1 translocation. | Q33187686 | ||
| Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. | Q33194953 | ||
| Single nucleotide polymorphisms modify the transporter activity of ABCG2. | Q33214177 | ||
| Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization | Q33240063 | ||
| Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells | Q33247258 | ||
| Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy | Q33247937 | ||
| Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. | Q33285468 | ||
| Genetic support for a quantitative trait nucleotide in the ABCG2 gene affecting milk composition of dairy cattle | Q33288487 | ||
| The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. | Q33304788 | ||
| Localisation of breast cancer resistance protein in microvessel endothelium of human brain | Q33962609 | ||
| Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs | Q34059522 | ||
| Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo | Q34156054 | ||
| The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein | Q34235311 | ||
| VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein | Q34304819 | ||
| ATP-binding cassette transporters in bacteria | Q34326023 | ||
| Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. | Q34369690 | ||
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. | Q34388548 | ||
| Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates | Q34446056 | ||
| A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants | Q34488592 | ||
| Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. | Q34491784 | ||
| The blood-brain barrier and cancer: transporters, treatment, and Trojan horses | Q34577796 | ||
| ABC transporters and inhibitors: new targets, new agents. | Q35023165 | ||
| Aberrant promoter methylation of the ABCG2 gene in renal carcinoma | Q35131563 | ||
| Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells | Q35612557 | ||
| Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk | Q35641888 | ||
| Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells | Q35837565 | ||
| ABCG2 expression, function, and promoter methylation in human multiple myeloma | Q35848835 | ||
| Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction | Q35848938 | ||
| Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense | Q36104162 | ||
| Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. | Q36120816 | ||
| Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein | Q36466963 | ||
| Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). | Q36691571 | ||
| ABCG2: determining its relevance in clinical drug resistance | Q36745478 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3-13 | |
| P577 | publication date | 2008-12-16 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | ABCG2: a perspective | |
| P478 | volume | 61 |
| Q34502756 | 17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity |
| Q34208237 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin induced cell-specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells. |
| Q88869027 | A New Class of 1-Aryl-5,6-dihydropyrrolo[2,1-a]isoquinoline Derivatives as Reversers of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells |
| Q36204229 | A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk |
| Q36386154 | A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier |
| Q47742323 | A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP. |
| Q37789041 | ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders |
| Q37782354 | ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison |
| Q38651433 | ABCG2 c.421C>A is Associated with Outcomes Following Severe Traumatic Brain Injury |
| Q37287637 | ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan |
| Q35318963 | ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. |
| Q46418563 | ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression |
| Q37885400 | ABCG2 transporter: therapeutic and physiologic implications in veterinary species |
| Q39049159 | ABCG2/BCRP: Specific and Nonspecific Modulators. |
| Q54104981 | ATP Binding Cassette Sub-family Member 2 (ABCG2) and Xenobiotic Exposure During Early Mouse Embryonic Stem Cell Differentiation. |
| Q34843023 | ATP-binding cassette efflux transporters in human placenta |
| Q46550033 | Acute liver failure impairs function and expression of breast cancer-resistant protein (BCRP) at rat blood-brain barrier partly via ammonia-ROS-ERK1/2 activation |
| Q39486373 | Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity |
| Q40735543 | Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. |
| Q64967468 | Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances. |
| Q37378512 | An intracellular trafficking pathway in the seminiferous epithelium regulating spermatogenesis: a biochemical and molecular perspective |
| Q36050053 | Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway |
| Q89638257 | Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population |
| Q51545799 | BCRP at the Blood−Brain Barrier: Genomic Regulation by 17β-Estradiol |
| Q35691501 | BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer |
| Q35030142 | Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice |
| Q89289786 | Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection |
| Q26864317 | Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke |
| Q34188579 | Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells |
| Q36072110 | Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation |
| Q37961977 | Cancer stem cell epigenetics and chemoresistance. |
| Q37178591 | Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines |
| Q38160088 | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions |
| Q28543911 | Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor |
| Q27851688 | Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study |
| Q46655056 | Comparison of chemotherapeutic drug resistance in cells transfected with canine ABCG2 or feline ABCG2. |
| Q58599978 | Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states |
| Q30364846 | Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2). |
| Q37604379 | Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues |
| Q42222444 | Dietary plant extracts modulate gene expression profiles in ileal mucosa of weaned pigs after an Escherichia coli infection. |
| Q24316869 | Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2 |
| Q49346936 | Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1. |
| Q37760954 | Drug transporter pharmacogenetics in nucleoside-based therapies. |
| Q42459205 | Drug transporter, P-glycoprotein (MDR1), is an integrated component of the mammalian blood-testis barrier |
| Q39304518 | Dynamic ABCG2 expression in human embryonic stem cells provides the basis for stress response. |
| Q38310909 | E2F1 drives chemotherapeutic drug resistance via ABCG2. |
| Q38699248 | Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells. |
| Q39492357 | Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells |
| Q39290800 | Efflux proteins at the blood-brain barrier: review and bioinformatics analysis |
| Q48524331 | Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. |
| Q34414027 | Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma |
| Q42709553 | Endocrine disruptors differentially target ATP-binding cassette transporters in the blood-testis barrier and affect Leydig cell testosterone secretion in vitro. |
| Q33796082 | Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. |
| Q42453248 | Evaluation of ABCG2 and p63 expression in canine cornea and cultivated corneal epithelial cells |
| Q38384387 | Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. |
| Q39278805 | Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines |
| Q35538429 | Expression of BAF57 in ovarian cancer cells and drug sensitivity |
| Q55412827 | Expression of CD44, CD44v9, ABCG2, CD24, Bmi-1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors. |
| Q37790379 | Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy |
| Q33980380 | Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. |
| Q89977752 | From Synthesis to Utilization: The Ins and Outs of Mitochondrial Heme |
| Q90021328 | Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort |
| Q36615181 | Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. |
| Q51460367 | Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse. |
| Q36335981 | Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2. |
| Q34179757 | Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter |
| Q33506860 | Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). |
| Q35186322 | Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. |
| Q33997565 | Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity |
| Q42043480 | Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences. |
| Q62512297 | Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients |
| Q36108251 | Improving cancer chemotherapy with modulators of ABC drug transporters |
| Q38730592 | In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus |
| Q35782792 | In vitro blood-brain barrier models: current and perspective technologies |
| Q34476565 | In vitro cerebrovascular modeling in the 21st century: current and prospective technologies |
| Q39683616 | In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice. |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q64062639 | Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications |
| Q42747845 | Inhibitory effects of Hedyotis diffusa Willd. on colorectal cancer stem cells |
| Q33614494 | Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance |
| Q32182119 | Interaction of mammary bovine ABCG2 with AFB1 and its metabolites and regulation by PCB 126 in a MDCKII in vitro model |
| Q42603051 | International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). |
| Q38379295 | Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles |
| Q34470778 | Kinetic analysis of intracellular Hoechst 33342--DNA interactions by flow cytometry: misinterpretation of side population status? |
| Q33860877 | MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport |
| Q34184787 | Mechanisms of membrane transport of folates into cells and across epithelia |
| Q29616802 | Membrane transporters in drug development |
| Q21195215 | MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer |
| Q57812851 | Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity |
| Q58593549 | Modulation of intestinal transport and absorption of topotecan, a BCRP substrate by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter |
| Q36958324 | Molecular mechanisms of statin intolerance |
| Q91608787 | Morphological and immunohistochemical characteristics of the equine corneal epithelium |
| Q33718824 | Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. |
| Q34496694 | Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways |
| Q61453624 | NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells |
| Q38883165 | Natural Polyphenols in Cancer Chemoresistance. |
| Q37193073 | Overlapping substrate and inhibitor specificity of human and murine ABCG2. |
| Q36953090 | PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo |
| Q26777643 | Pathobiology of tobacco smoking and neurovascular disorders: untied strings and alternative products |
| Q46018199 | PharmGKB summary: very important pharmacogene information for ABCG2. |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37875115 | Pharmacogenomics and adverse drug reactions: the case of statins |
| Q36734138 | Pharmacokinetics of drugs in pregnancy |
| Q35585820 | Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics. |
| Q37082646 | Placental expression of the heme transporter, feline leukemia virus subgroup C receptor, is related to maternal iron status in pregnant adolescents. |
| Q37686521 | Population-specific association between ABCG2 variants and tophaceous disease in people with gout |
| Q42676608 | Positive regulation of the Candida albicans multidrug efflux pump Cdr1p function by phosphorylation of its N-terminal extension. |
| Q38282100 | Potency of non-steroidal anti-inflammatory drugs in chemotherapy. |
| Q84007319 | Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial |
| Q38166961 | Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. |
| Q51749326 | Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity. |
| Q37604385 | Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines |
| Q32181276 | Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling |
| Q38514267 | Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites |
| Q36027132 | Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs |
| Q50642121 | Role of STAT5 and epigenetics in lactation-associated upregulation of multidrug transporter ABCG2 in the mammary gland. |
| Q33890952 | Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport |
| Q26865927 | Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance |
| Q34211113 | Role of breast cancer resistance protein in the adaptive response to cholestasis |
| Q28548494 | SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer |
| Q37311636 | Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. |
| Q89642081 | Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease |
| Q38068912 | Species differences in drug transporters and implications for translating preclinical findings to humans |
| Q28482973 | StarD7 knockdown modulates ABCG2 expression, cell migration, proliferation, and differentiation of human choriocarcinoma JEG-3 cells |
| Q36413366 | Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma |
| Q88249559 | Structural basis of small-molecule inhibition of human multidrug transporter ABCG2 |
| Q34176588 | Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) |
| Q41597764 | Structure of the human multidrug transporter ABCG2. |
| Q48344291 | Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. |
| Q37560771 | Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). |
| Q35855634 | Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery |
| Q37317194 | Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells |
| Q28088708 | Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury |
| Q37059699 | The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system |
| Q91525910 | The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid |
| Q37810986 | The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins |
| Q36790321 | The Lipid Transfer Protein StarD7: Structure, Function, and Regulation |
| Q28395237 | The blood-testis barrier and its implications for male contraception |
| Q38089090 | The controversy of a wider statin utilization: why? |
| Q40147815 | The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone |
| Q34631971 | The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins |
| Q36332448 | The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2. |
| Q35927508 | Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation |
| Q37963498 | Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies |
| Q33672739 | Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q37735146 | Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy |
| Q57684264 | Transporters in Drug Discovery |
| Q84437444 | Transverse and tangential orientation of predicted transmembrane fragments 4 and 10 from the human multidrug resistance protein (hMRP1/ABCC1) in membrane mimics |
| Q37190973 | Tumorigenic lung tumorospheres exhibit stem-like features with significantly increased expression of CD133 and ABCG2. |
| Q37151581 | Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats |
| Q39584939 | Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. |
| Q52721223 | Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. |
| Q35776784 | Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance |
Search more.